The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention

Abstract

5α-reductase inhibitors' potential benefits in preventing prostate cancer and potential increased risk for high-grade cancers have been central issues for the FDA, which convened its Oncologic Drugs Advisory Committee to address the topic last December.